[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"anti-vascular-endothelial-growth-factor\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:anti-vascular-endothelial-growth-factor":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,80],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100611049","real-life-clinical-outcomes-of-aflibercept-biosimilar-my-1701p-in-the-treatment-of-exudative-age-related-macular-degeneration-100611049",false,"NCT07235527","Real-Life Clinical Outcomes of Aflibercept Biosimilar MY-1701P in the Treatment of Exudative Age-Related Macular Degeneration","Real-World Outcomes of Aflibercept Biosimilar MY-1701P Treatment in Exudative Age-Related Macular Degeneration","Inclusion Criteria:\n\n* Patients aged between 45 and 90 years with active neovascular age-related macular degeneration (nAMD)\n* who show signs of disease activity on routine ophthalmologic examination and optical coherence tomography (OCT)\n* for whom intravitreal injection has already been clinically indicated\n\nExclusion Criteria:\n\n* Patients younger than 45 years or older than 90 years\n* History of stroke, cerebrovascular event, myocardial infarction, or coronary stent placement within the last six months\n* Presence of uveitis\n* Media opacity preventing adequate retinal imaging (e.g., corneal opacity, mature cataract)\n* Coexistence of other retinal vascular diseases (e.g., branch retinal vein occlusion, diabetic macular edema)\n* Presence of hereditary retinal dystrophies\n* Presence of optic atrophy","ALL","45 Years","90 Years",{"count":20,"type":21},54,"ESTIMATED","OBSERVATIONAL","In this study, patients receiving Eylea treatment will be treated with Yesafili, a biosimilar molecule, and routine examination results will be noted.",[25,26,27],"Age Related Macular Degeneration","Exudative Age-Related Macular Degeneration","Anti Vascular Endothelial Growth Factor",[29,30,31,32,33,34],"age related macular degeneration","anti vascular endothelial growth factor","anti-VEGF","aflibercept","macular neovascularization","aflibercept biosimilar","RECRUITING","2025-12-05",{"date":38,"type":39},"2025-12-08","ACTUAL",{"date":41,"type":39},"2025-11-20",{"date":43,"type":21},"2026-08-20",{"name":45,"class":46},"Saglik Bilimleri Universitesi","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":65,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":76,"leadSponsor":78,"locationsCount":47},"100607380","phase-4-long-term-efficacy-of-faricimab-using-a-treat-and-extend-regimen-for-type-3-macular-neovascularization-100607380","NCT07187804","Long Term Efficacy of Faricimab Using a Treat and Extend Regimen for Type 3 Macular Neovascularization","Inclusion Criteria:\n\n\\[General\\]\n\n* Signed Informed Consent Form\n* Age \\> 50 years at the time of signing Informed Consent Form\n* Participants who are able to comply with the study protocol, in the investigator's judgment\n* For female participants of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception (will be defined in details in protocol)\n\n\\[Ocular\\]\n\n* BCVA that is equal or higher than 24 Early Treatment Diabetic Retinopathy Study letters on Screening Day\u002F Day 0.\n* Confirmed diagnosis, by the investigator, of symptomatic type 3 neovascularization based on sufficiently clear ocular media and adequate pupillary dilatation allowing acquisition of good quality retinal images for confirmation.\n* Treatment naive participants\n\nExclusion Criteria:\n\n\\[General\\]\n\n* Treatment with investigational therapy (device, drug, or traditional medicine with the exception of vitamins and minerals) within 3 months prior to initiation of study treatment on study Day 1\n* Any major illness or major surgical procedure within 1 month before screening\n* Active cancer within the 12 months prior to study Day 1 except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, and prostate cancer with a Gleason score of \\\u003C 6 (Grade Group of 1) and a stable prostate-specific antigen for \\>12 months\n* Continuous use of any medications and treatments (which will be indicated in the Prohibited Therapy section in protocol)\n* Systemic treatment for suspected or active systemic infection on study Day 1\n* Uncontrolled blood pressure, defined as systolic blood pressure \\> 180 mmHg and\u002For diastolic blood pressure \\> 100 mmHg while the participant is at rest on study Day 1\n* History of stroke (cerebral vascular accident) or myocardial infarction within 6 months prior to study Day 1\n* History of other disease, metabolic dysfunction, physical examination finding, or historical or current clinical laboratory findings giving reasonable suspicion of a condition that contraindicates the use of the investigational drug or that might affect interpretation of the results of the study or renders the participant at high risk for treatment complications in the opinion of the investigator\n* History of severe allergic reaction or anaphylactic reaction to a biologic agent or known hypersensitivity to any component of the faricimab injection, study-related procedure preparations (including fluorescein and indocyanine green dyes), dilating drops, or any of the anesthetic and antimicrobial preparations used by a participant during the study\n* Pregnancy or breastfeeding, or intention of becoming pregnant during the study or within 28 days after the final dose of faricimab\n\n\\[Ocular\\]\n\n* Significant media opacities, including cataract, in the study eye that might interfere with visual acuity, assessment of safety, or fundus photography.\n* Any concurrent ocular condition in the study eye which, in the opinion of the investigator, could either increase the risk to the patient beyond what is to be expected from standard procedures of intraocular injection, or which otherwise may interfere with the injection procedure or with evaluation of efficacy or safety.\n\nAny ocular or periocular infection within the last 2 weeks prior to Screening in either eye.\n\n* Any history of uveitis in either eye.\n* Presence of definite chorioretional anastomosis\n* Subretinal hemorrhage that is either 50% or more of the total lesion area, or if the blood is under the fovea and is 1 or more disc areas in size in the study eye. (If the blood is under the fovea, then the fovea must be surrounded 270 degrees by visible macular neovascularization.)\n* Scar or fibrosis, making up \\> 50% of total lesion in the study eye.\n* Scar, fibrosis, or atrophy involving the center of the fovea in the study eye.\n* Presence of retinal pigment epithelial tears or rips involving the macula in the study eye.\n* History or clinical evidence of diabetic retinopathy, diabetic macular edema or any other vascular disease affecting the retina, other than AMD, in either eye.\n* Any concurrent intraocular condition in the study eye (e.g. cataract) that, in the opinion of the investigator, could require either medical or surgical intervention during the 76 week study period.\n* Prior vitrectomy in the study eye\n* Any history of macular hole of stage 2 and above in the study eye.\n* Any intraocular or periocular surgery within 3 months of Day 1 on the study eye, except lid surgery, which may not have taken place within 1 month of day 1, as long as it's unlikely to interfere with the injection.\n* Prior trabeculectomy or other filtration surgery in the study eye.\n* Uncontrolled glaucoma (defined as intraocular pressure ≥ 25 mmHg despite treatment with antiglaucoma medication) in the study eye.\n* Active intraocular inflammation in either eye.\n* Active ocular or periocular infection in either eye.\n* Aphakia or pseudophakia with absence of posterior capsule (unless it occurred as a result of an yttrium aluminum garnet \\[YAG\\] posterior capsulotomy) in the study eye.","50 Years",{"count":56,"type":21},30,"INTERVENTIONAL",[59],"PHASE4","Type 3 macular neovascularization (MNV) is a subtype of neovascular age-related macular degeneration accounting for 10-20% of cases, notable for high rates of bilateral involvement and risk of profound vision loss, particularly if undertreated. Early and proactive therapy is crucial to prevent progression and preserve vision.\n\nFaricimab offers potential advantages in this setting. Eyes with type 3 MNV often show thin choroid, reticular pseudodrusen, and high GA risk, reflecting compromised choroidal perfusion. While anti-vascular endothelial growth factor (VEGF) agents suppress neovascularization, prolonged VEGF blockade may impair choriocapillaris health. Ang-2 inhibition, by promoting Tie2 activation and vascular stability, may protect choriocapillaris and reduce widespread retinal edema and hemorrhages observed in type 3 MNV.\n\nFinally, while treat-and-extend is widely used in practice, existing trials (TENAYA, LUCERNE) applied broader extension intervals than typically used clinically. In type 3 MNV, where undertreatment carries severe consequences, a more stringent faricimab-based treat-and-extend regimen with 2-week interval adjustments warrants investigation.",[62,63,64],"Age-related Macular Degeneration (ARMD)","Choroidal Neovascularization","Anti-vascular Endothelial Growth Factor",[66,67,68,69,70],"Age-related macular degeneration","Type 3 macular neovascularization","Retinal angiomatous proliferation","Faricimab","Treat and extend","NOT_YET_RECRUITING","2025-09-19",{"date":74,"type":39},"2025-09-23",{"date":74,"type":21},{"date":77,"type":21},"2028-09-22",{"name":79,"class":46},"Kim's Eye Hospital",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":16,"minAge":88,"maxAge":18,"enrollmentInfo":89,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":91,"conditions":92,"keywords":95,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":47},"100537033","exploring-the-interaction-between-metabolic-disorders-and-nlpr3-inflammasome-activation-in-dr-inflammatory-damage-100537033","NCT06272565","Exploring the Interaction Between Metabolic Disorders and NLPR3 Inflammasome Activation in DR Inflammatory Damage","An Approach of Exploring the Mechanism of the Interaction Between Metabolic Disorders and NLPR3 Inflammasome Activation in DR Inflammatory Damage Based on Metabolomics Methods","DR","Inclusion Criteria:\n\n1. Patients \\> 40 years old.\n2. CON (non diabetes control group)：patients undergoing phacoemulsification surgery.\n3. NDR (non diabetes retinopathy diabetes patients): patients with diabetes history and undergoing phacoemulsification surgery.\n4. NPDR (non proliferative diabetes retinopathy): patients with history of diabetes, fundus microangiopathy shown by fundus fluorescein angiography, including microangioma, hard exudation, wadding exudation and other non proliferative diabetes retinopathy signs, and did not receive invasive ophthalmic treatment within 3 months.\n5. PDR (proliferative diabetes retinopathy): patients with a history of diabetes, fundus neovascular lesions shown by fundus fluorescein angiography, and did not receive invasive ophthalmic treatment within 3 months.\n6. Patients voluntarily signed informed consent.\n\nExclusion Criteria:\n\n1. CON (non diabetes control group)：patients with a history of other ophthalmic operations.\n2. NDR (non diabetes retinopathy diabetes patients): patients with fundus changes of diabetes retinopathy or other ophthalmic surgery history.\n3. NPDR (non proliferative diabetes retinopathy): patients with fundus neovascular lesions shown by fundus fluorescein angiography.\n4. PDR (proliferative diabetes retinopathy):patients undergoing vitrectomy。\n5. Patients with active ocular inflammation, high myopia, pregnancy.","40 Years",{"count":90,"type":21},240,"Diabetic retinopathy (DR) is one of the most serious microvascular complications of diabetes. Early diagnosis and treatment of diabetes is the key to prevent visual impairment in DR patients. This study aims to use a non-targeted metabolomics detection technique combined with ultra-high performance liquid chromatography time-of-flight mass spectrometry to analyze the metabolomics profile in aqueous humor sample of DR patents, and further explore the mechanism of the relationship between differential metabolites and their metabolic pathways with NLRP3 activation in DR inflammatory damage. DR patients with macular edema will receive anti-vascular endothelial growth factor (anti-VEGF) treatment; these patients will be divided into two groups: responders group and non-responders group.",[93,94,64],"Diabetic Retinopathy","Diabetic Macular Edema",[96,97,98,99,100],"Diabetic retinopathy","metabolomics","NLPR3","Diabetic Macular edema","Anti-vascular endothelial growth factor","2024-06-27",{"date":103,"type":39},"2024-07-01",{"date":105,"type":21},"2024-07-03",{"date":107,"type":21},"2026-12-30",{"name":109,"class":46},"Zhongshan Ophthalmic Center, Sun Yat-sen University"]